8/4/2020 7:08:49 AM
Karyopharm Therapeutics Q2 Net Loss $46.4 Mln Or $0.63/shr Vs. Net Loss $43.4 Mln Or $0.71/shr Last Year
7/20/2020 7:22:33 AM
Karyopharm: FDA Accept SNDA For XPOVIO For Patients With Multiple Myeloma After At Least One Prior Line Of Therapy
7/14/2020 7:16:34 AM
Karyopharm Expects Net Product Sales Of XPOVIO To Be $18.5 Mln For Q2
6/24/2020 7:16:44 AM
Karyopharm Publishes XPOVIO Phase 2b SADAL Study Results In The Lancet Haematology
3/12/2020 7:24:14 AM
Karyopharm Therapeutics Appoints John Demaree As Chief Commercial Officer
3/3/2020 7:57:48 PM
Karyopharm Therapeutics Prices Registered Underwritten Public Offering Of 6.25 Mln Shares At $24.00/shr
2/28/2020 7:03:23 AM
Karyopharm Therapeutics Adds Richard Paulson To Its Board
1/13/2020 7:14:21 AM
Karyopharm Expects XPOVIO Unaudited Net Product Sales Of $17 Mln-$18 Mln For Q4 And $30 Mln-$31 Mln For 2019
10/1/2019 7:16:30 AM
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10/1/2019 7:15:29 AM
Karyopharm Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/16/2019 7:17:40 AM
Karyopharm Enters Into Royalty Agreement With Healthcare Royalty Partners For Up To $150 Mln
7/5/2019 7:51:23 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) FY19 Rev. Estimate To 9.2 M From 5.5 M
7/5/2019 7:51:09 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q4 19 Rev. Estimate To 5.8 M From 4.2 M